Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy

Circulation

Volumn 97, Issue 22, 1998, Pages 2259-2267

  Vakeva, Antti P ^c   Agah, Azin ^a   Rollins, Scott A ^b   Matis, Louis A ^b   Li, Lan ^b   Stahl, Gregory L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Complement C3b; Complement C5; Infarction; Reperfusion

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16C; MONOCLONAL ANTIBODY 18A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOLYSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 0032499629     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.22.2259     Document Type: Article

References (46)

1. Pinckard RN, O'Roarke RA, Crawford MH. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest. 1980;66:1050-1056.
2. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 1986;137:1945-1949.
3. Rossen RD, Swain JL, Michael LH. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle: a possible initiator of an extra myocardial mechanism of ischemic injury. Circ Res. 1985;57:119-130.
4. Vakeva A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol. 1993;143:65-75.
5. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts in rats. J Exp Med. 1971;133:885-900.
6. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
7. Maroko PR, Carpenter CB, Chariello M. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978;61:661-670.
8. Weisman HF, Bartow T, Leppo MK, Marsh HCJ, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1 : in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-151.
9. Ross GD, Medof ME. Membrane complement receptors specific for bound fragments of C3. Adv Immunol. 1985;37:217-267.
10. Chenoweth DE. The properties of human C5a anaphylaloxin: the significance of C5a formation during hemodialysis. Contrib Nephrol. 1987;59: 51-71.
11. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PS. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem. 1989;264:7768-7771.
12. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147-1155.
13. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart: role of the terminal complement components. Circ Res. 1992;71:303-319.
14. 2, Mac-1) and promotes leukocyte adhesion. J Biol Chem. 1993;268:1847-11853.
15. Stahl GL, Reenstra WR, Frendl G. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries: role of the terminal membrane attack complex. Circ Res. 1995;76:575-583.
16. Lennon PF, Collard CD, Morrissey MA, Stahl GL. Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences. Am J Physiol. 1996;270(Heart Circ Physiol 39): H1924-H1932.
17. Friedman M, Wang SY, Stahl GL, Johnson RG, Sellke FW. Altered β3-adrenergic and cholinergic pulmonary vascular responses after total cardiopulmonary bypass. J Appl Physiol. 1995;79:1998-2006.
18. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 1996;79:949-956.
19. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 1994;75:426-433.
20. James TN. Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias. Circulation. 1994;90:556-573.
21. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621-1628.
22. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L-M. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320-323.
23. Long X, Boluyt MO, Hipolito ML, Lundberg MS, Zheng J-S, O'Neill L, Cirielli C, Lakatta EG, Crow MT. p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. J Clin Invest. 1997;99:2635-2643.
24. Bialik S, Geenen DL, Sasson IE, Cheng R, Horner JW, Evans SM, Lord EM, Koch CJ, Kitsis RN. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest. 1997;100:1363-1372.
25. Niculescu F, Rus H, Van Biesen T, Shin ML. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol. 1997;158:4405-4412.
26. Buhl AM, Avdi N, Worthen GS, Johnson GL, Mapping of the C5a receptor signal transduction network in human neutrophils. Proc Natl Acad Sci U S A. 1994;91:9190-9194.
27. Amsterdam EA Stahl GL, Pan H-L, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268(Heart Circ Physiol 37):H448-H457.
28. Van den Berg CW, Van Dijk H, Capel PJA. Rapid isolation and characterization of native mouse complement components C3 and C5. J Immunol Methods. 1989;122:73-80.
29. Stahl GL, Fletcher MP, Amsterdam EA, Longhurst JC. Role of granulocytes and C5a in myocardial response to zymosan-activated serum. Am J Physiol. 1991;261(Heart Circ Physiol 30):H29-H37.
30. Colgan SP, Balancquaert A-MB, Thrall MA, Bruyninckx WJ. Defective in vitro motility of polymorphonuclear leukocytes of homozygote and heterozygote Chediak-Higashi cats. Vet Immunol Immunopathol. 1992; 31:205-227.
31. Stahl GL, Terashita Z-I, Lefer AM. Role of platelet activating factor in propagation of cardiac damage during myocardial ischemia. J Pharmacol Exp Ther. 1988;244:898-904.
32. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest. 1989;83:465-473.
33. Griswold DE, Hillegass LM, Hill DE, Egan JW, Smith EF III. Method for quantification of myocardial infarction and inflammatory cell infiltration in rat cardiac tissue. J Pharmacol Methods. 1988;20:225-235.
34. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW. Inflammation in the course of early myocardial ischemia. FASEB J. 1991;5:2529-2537.
35. Lucchesi BR. Complement activation, neutrophils, and oxygen radicals in reperfusion injury. Stroke. 1993;24:41-47.
36. Lefer AM, Weyrich AS, Buerke M. Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury. Cardiovasc Res. 1994;28:289-294.
37. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P, Becker P, Darius H, Rupprecht H-J, Loos M, Bhakdi S, Meyer J, Kempski O. Intracoronary application of Cl esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 1997;95:701-708.
38. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264:9053-9060.
39. Marks RM, Todd RFI, Ward PA. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation, Nature. 1989;339: 314-317.
40. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol. 1997;150:2019-2031.
41. Dreyer WJ, Michael LH, Nguyen T, Smith CW, Anderson DC, Entman ML, Rossen RD. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury. Circ Res. 1992; 71:1518-1524.
42. Halperin JA, Taratuska A, Rynkiewicz M, Nicholson-Weller A. Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood. 1993;81:200-205.
43. Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res. 1993;12:244-257.
44. Berger H-J, Taratuska A, Smith TW, Halperin JA. Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. Am J Physiol. 1993;265:H267-H272.
45. Morgan BP. Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol. 1992;178:115-140.
46. Agah A, Vakeva A, Morse DS, Rollins SA, Stahl GL. Complement-induced apoptosis in vitro and in vivo: role of the terminal complement complex. C5b-9. Microcirculation. 1997;4:171. Abstract.